285 related articles for article (PubMed ID: 28832222)
1. Natalizumab in the treatment of Crohn's disease patients.
Pagnini C; Arseneau KO; Cominelli F
Expert Opin Biol Ther; 2017 Nov; 17(11):1433-1438. PubMed ID: 28832222
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab for induction of remission in Crohn's disease.
MacDonald JK; McDonald JW
Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
[TBL] [Abstract][Full Text] [Related]
3. Natalizumab for induction of remission in Crohn's disease.
Macdonald JK; McDonald JW
Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
[TBL] [Abstract][Full Text] [Related]
4. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
McLean LP; Cross RK
Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
[TBL] [Abstract][Full Text] [Related]
5. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn's disease.
Ko HH; Bressler B
Expert Rev Gastroenterol Hepatol; 2007 Oct; 1(1):29-39. PubMed ID: 19072431
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Natalizumab and Vedolizumab for the Management of Crohn's Disease: A Systematic Review and Meta-analysis.
Chandar AK; Singh S; Murad MH; Peyrin-Biroulet L; Loftus EV
Inflamm Bowel Dis; 2015 Jul; 21(7):1695-708. PubMed ID: 25856769
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of Antibodies Against JC Virus in Patients With Refractory Crohn's Disease and Effects of Natalizumab Therapy.
Bellaguarda E; Keyashian K; Pekow J; Rubin DT; Cohen RD; Sakuraba A
Clin Gastroenterol Hepatol; 2015 Nov; 13(11):1919-25. PubMed ID: 26001336
[TBL] [Abstract][Full Text] [Related]
8. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals.
Juillerat P; Wasan SK; Fowler SA; Friedman S; Pabby VK; Coukas JA; Barto AE; Pellish R; Germansky KA; Cheifetz AS; Korzenik JR; Farraye FA; Yajnik V
Inflamm Bowel Dis; 2013 Oct; 19(11):2457-63. PubMed ID: 23962896
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology.
Shirani A; Stüve O
J Immunol; 2017 Feb; 198(4):1381-1386. PubMed ID: 28167648
[TBL] [Abstract][Full Text] [Related]
11. Anti-integrin therapy for inflammatory bowel disease.
Park SC; Jeen YT
World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab for the treatment of Crohn's disease.
Bickston SJ; Muniyappa K
Expert Rev Clin Immunol; 2010 Jul; 6(4):513-9. PubMed ID: 20594122
[TBL] [Abstract][Full Text] [Related]
13. Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
Shivashankar R; Pardi DS
Gastroenterol Clin North Am; 2017 Sep; 46(3):589-601. PubMed ID: 28838417
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.
Ghosh S
Expert Opin Biol Ther; 2003 Sep; 3(6):995-1000. PubMed ID: 12943458
[TBL] [Abstract][Full Text] [Related]
15. [Natalizumab for the treatment of Crohns disease: Report of three cases].
Fluxá D; Ibáñez P; Flores L; Figueroa C; Lubascher J; Kronberg U; Simian D; Pizarro G; Toche P; Quera R
Rev Med Chil; 2017 Apr; 145(4):538-543. PubMed ID: 28749002
[TBL] [Abstract][Full Text] [Related]
16. What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn's Disease Treated With Vedolizumab?
Card T; Xu J; Liang H; Bhayat F
Inflamm Bowel Dis; 2018 Apr; 24(5):953-959. PubMed ID: 29668955
[TBL] [Abstract][Full Text] [Related]
17. New biologic therapeutics for ulcerative colitis and Crohn's disease.
Mozaffari S; Nikfar S; Abdolghaffari AH; Abdollahi M
Expert Opin Biol Ther; 2014 May; 14(5):583-600. PubMed ID: 24502344
[TBL] [Abstract][Full Text] [Related]
18. Targeting Specific Immunologic Pathways in Crohn's Disease.
Ramos GP; Faubion WA; Papadakis KA
Gastroenterol Clin North Am; 2017 Sep; 46(3):577-588. PubMed ID: 28838416
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ; Colombel JF; Enns R; Feagan BG; Hanauer SB; Lawrance IC; Panaccione R; Sanders M; Schreiber S; Targan S; van Deventer S; Goldblum R; Despain D; Hogge GS; Rutgeerts P; ;
N Engl J Med; 2005 Nov; 353(18):1912-25. PubMed ID: 16267322
[TBL] [Abstract][Full Text] [Related]
20. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.
Gordon FH; Lai CW; Hamilton MI; Allison MC; Srivastava ED; Fouweather MG; Donoghue S; Greenlees C; Subhani J; Amlot PL; Pounder RE
Gastroenterology; 2001 Aug; 121(2):268-74. PubMed ID: 11487536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
